InvestorsHub Logo
Followers 74
Posts 15841
Boards Moderated 0
Alias Born 04/26/2010

Re: NickHous post# 267702

Monday, 04/20/2020 5:17:20 PM

Monday, April 20, 2020 5:17:20 PM

Post# of 426154

Am I not thinking right?



Yes.

Does the medicinal and scientific "ruler of the US" (the FDA) not carry the final say-so in this matter?



No - FDA is not in the business of deciding whether patents are valid, or which ones will or could be infringed if they approve a generic, that's up to the courts. Everybody who is thinking the FDA could or would somehow reject or delay ANDAs in order to benefit AMRN to make this debacle "more fair" is barking up the wrong tree. Whether the FDA starts looking closer at the ANDAs now that AMRN lost in court or continues to dawdle because of the appeal I have no idea, but JT wouldn't be talking about injunctions and at-risk launches if he thought the FDA was going to just sit on it's hands until the appeal is decided. That said, with the news that AMRN's API suppliers were approached by generics and were rebuffed, I don't think a generic is actually going to be able to produce GV caps for the FDA to analyze anytime soon, and if generics cannot produce GV the FDA can't advance their ANDAs, so FDA will essentially just sit on it's hands, but not because they made a conscious decision to do so.

The Thought Police: To censor and protect. Craig Bruce

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News